ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

CLAUDE RESIL M.D.

2110 DORCHESTER AVE SETON MEDICAL BUILDING, SUITE 205

Dorchester | Massachusetts | 02124

(617) 298-8304

Incorrect Info?
Search this name in Dollars for Docs »
See this provider's services »

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,648Medicare Part D Prescriptions Filled, Including Refills

Rank: 196 out of 2456

$461K Total Retail Price of All Prescriptions

Rank: 270 out of 2456

294 Patients Receiving at Least One Drug in Part D
83%Patients 65 Years and Older
95% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Massachusetts
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

2% of this provider’s 8,557 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$48 was the average price of a prescription from this provider, compared to $56 among peers.

Prescriptions per Patient

33 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Massachusetts
SIMVASTATIN 526 501 1 2
HYDROCHLOROTHIAZIDE 500 471 2 7
OMEPRAZOLE 471 436 3 3
AMLODIPINE BESYLATE 399 372 4 5
METFORMIN HCL 390 364 5 11
LISINOPRIL 371 339 6 1
FUROSEMIDE 360 330 7 8
LOSARTAN POTASSIUM 252 212 8 18
JANUVIA 202 188 9 81
IBUPROFEN 192 162 10 52
DOXAZOSIN MESYLATE 184 158 11 71
METOPROLOL TARTRATE 174 171 12 10
GLIMEPIRIDE 172 170 13 74
GLIPIZIDE 165 159 14 46
NAMENDA 158 147 15 42
METOPROLOL SUCCINATE 145 140 16 13
ATENOLOL 144 95 17 6
GABAPENTIN 140 119 18 16
LOVASTATIN 132 118 19 34
DONEPEZIL HCL 124 124 20 23
LISINOPRIL-HYDROCHLOROTHIAZIDE 122 110 21 41
DIOVAN 119 117 22 26
CELEBREX 118 117 23 127
ATACAND 102 102 24 358
MICARDIS 93 93 25 291
ALENDRONATE SODIUM 86 80 26 19
AMITRIPTYLINE HCL 84 71 R 27 83
MECLIZINE HCL 83 83 28 107
FINASTERIDE 81 81 29 66
METFORMIN HCL ER 79 76 30 59
HYDRALAZINE HCL 77 63 31 105
RANITIDINE HCL 75 64 32 31
PROAIR HFA 70 50 33 22
PANTOPRAZOLE SODIUM 66 51 34 37
CRESTOR 65 51 35 25
TAMSULOSIN HCL 64 60 36 32
TRAZODONE HCL 61 60 37 17
FLUTICASONE PROPIONATE 60 51 38 30
GLIPIZIDE XL 59 58 39 168
LANTUS 58 52 40 44
CYCLOBENZAPRINE HCL 57 16 R 41 77
CLONIDINE HCL 55 43 42 111
CYPROHEPTADINE HCL 55 54 R 42 468
MELOXICAM 55 55 42 121
SPIRONOLACTONE 53 50 45 73
OLANZAPINE 52 33 46 57
INSULIN SYRINGE 52 52 46 72
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 16, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.